Prefrontal cortex circuits in depression and anxiety: contribution of discrete neuronal populations and target regions

Our understanding of depression and its treatment has advanced with the advent of ketamine as a rapid-acting antidepressant and the development and refinement of tools capable of selectively altering the activity of populations of neuronal subtypes. This work has resulted in a paradigm shift away fr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Molecular psychiatry 2020-11, Vol.25 (11), p.2742-2758
Hauptverfasser: Hare, Brendan D., Duman, Ronald S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2758
container_issue 11
container_start_page 2742
container_title Molecular psychiatry
container_volume 25
creator Hare, Brendan D.
Duman, Ronald S.
description Our understanding of depression and its treatment has advanced with the advent of ketamine as a rapid-acting antidepressant and the development and refinement of tools capable of selectively altering the activity of populations of neuronal subtypes. This work has resulted in a paradigm shift away from dysregulation of single neurotransmitter systems in depression towards circuit level abnormalities impacting function across multiple brain regions and neurotransmitter systems. Studies on the features of circuit level abnormalities demonstrate structural changes within the prefrontal cortex (PFC) and functional changes in its communication with distal brain structures. Treatments that impact the activity of brain regions, such as transcranial magnetic stimulation or rapid-acting antidepressants like ketamine, appear to reverse depression associated circuit abnormalities though the mechanisms underlying the reversal, as well as development of these abnormalities remains unclear. Recently developed optogenetic and chemogenetic tools that allow high-fidelity control of neuronal activity in preclinical models have begun to elucidate the contributions of the PFC and its circuitry to depression- and anxiety-like behavior. These tools offer unprecedented access to specific circuits and neuronal subpopulations that promise to offer a refined view of the circuit mechanisms surrounding depression and potential mechanistic targets for development and reversal of depression associated circuit abnormalities.
doi_str_mv 10.1038/s41380-020-0685-9
format Article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7442605</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A639117945</galeid><sourcerecordid>A639117945</sourcerecordid><originalsourceid>FETCH-LOGICAL-c603t-a2f44d914d711e5627864ee14a227765564ab4deca4ea1f98fd9da7e9666c3</originalsourceid><addsrcrecordid>eNp1Ul1v1iAUJkbj5vQHeGOaeONNN6CUFi9MlkWnyRKXxXvCC6eVpS9UoMv27z313ea2aAiB8HzAOTyEvGX0kNGmP8qCNT2tKccp-7ZWz8g-E52s27brn-O-aVUtWC_2yKucLyldwfYl2Ws47aVoxD65Ok8wpBiKmSobU4HryvpkF19y5UPlYE6Qs4-hMsHhvPZQbj4iNZTkN0tZkThUzmeboEAVYEE3NJvjvExmxfMfaTFphFIlGNej1-TFYKYMb27XA3Lx5fOPk6_12ffTbyfHZ7WVtCm14YMQTjHhOsaglbzDZwMwYTjvsJRWCrMRDqwRYNig-sEpZzpQUkrbHJBPO9N52WzBWcA3m0nPyW9NutHReP0YCf6nHuOV7oTgkrZo8OHWIMVfC-Sit1gnTJMJEJeseSM5Va2iEqnvn1Av45KwEcgSHROKse4BazQTaB-GiPfa1VQfy2blKLFee_gPFg4HW4-dh8Hj-SMB2wlsijnjh97XyKhek6J3SdGYFL0mRSvUvHvYnHvFXTSQwHeEjFAYIf2t6P-uvwHIiMso</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2471491176</pqid></control><display><type>article</type><title>Prefrontal cortex circuits in depression and anxiety: contribution of discrete neuronal populations and target regions</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Hare, Brendan D. ; Duman, Ronald S.</creator><creatorcontrib>Hare, Brendan D. ; Duman, Ronald S.</creatorcontrib><description>Our understanding of depression and its treatment has advanced with the advent of ketamine as a rapid-acting antidepressant and the development and refinement of tools capable of selectively altering the activity of populations of neuronal subtypes. This work has resulted in a paradigm shift away from dysregulation of single neurotransmitter systems in depression towards circuit level abnormalities impacting function across multiple brain regions and neurotransmitter systems. Studies on the features of circuit level abnormalities demonstrate structural changes within the prefrontal cortex (PFC) and functional changes in its communication with distal brain structures. Treatments that impact the activity of brain regions, such as transcranial magnetic stimulation or rapid-acting antidepressants like ketamine, appear to reverse depression associated circuit abnormalities though the mechanisms underlying the reversal, as well as development of these abnormalities remains unclear. Recently developed optogenetic and chemogenetic tools that allow high-fidelity control of neuronal activity in preclinical models have begun to elucidate the contributions of the PFC and its circuitry to depression- and anxiety-like behavior. These tools offer unprecedented access to specific circuits and neuronal subpopulations that promise to offer a refined view of the circuit mechanisms surrounding depression and potential mechanistic targets for development and reversal of depression associated circuit abnormalities.</description><identifier>ISSN: 1359-4184</identifier><identifier>EISSN: 1476-5578</identifier><identifier>DOI: 10.1038/s41380-020-0685-9</identifier><identifier>PMID: 32086434</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/378 ; 692/699/476/1414 ; Antidepressants ; Antidepressive Agents - pharmacology ; Antidepressive Agents - therapeutic use ; Anxiety ; Anxiety - drug therapy ; Anxiety - pathology ; Behavioral Sciences ; Biological Psychology ; Brain ; Depression - drug therapy ; Depression - pathology ; Depression, Mental ; Ketamine ; Ketamine - pharmacology ; Ketamine - therapeutic use ; Magnetic fields ; Medicine ; Medicine &amp; Public Health ; Mental depression ; Neural Pathways - drug effects ; Neurons ; Neurosciences ; Pharmacotherapy ; Prefrontal cortex ; Prefrontal Cortex - drug effects ; Prefrontal Cortex - pathology ; Psychiatry ; Review Article ; Transcranial magnetic stimulation</subject><ispartof>Molecular psychiatry, 2020-11, Vol.25 (11), p.2742-2758</ispartof><rights>The Author(s), under exclusive licence to Springer Nature Limited 2020</rights><rights>COPYRIGHT 2020 Nature Publishing Group</rights><rights>The Author(s), under exclusive licence to Springer Nature Limited 2020.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c603t-a2f44d914d711e5627864ee14a227765564ab4deca4ea1f98fd9da7e9666c3</citedby><cites>FETCH-LOGICAL-c603t-a2f44d914d711e5627864ee14a227765564ab4deca4ea1f98fd9da7e9666c3</cites><orcidid>0000-0001-8690-8439 ; 0000-0002-6502-3188</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41380-020-0685-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41380-020-0685-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32086434$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hare, Brendan D.</creatorcontrib><creatorcontrib>Duman, Ronald S.</creatorcontrib><title>Prefrontal cortex circuits in depression and anxiety: contribution of discrete neuronal populations and target regions</title><title>Molecular psychiatry</title><addtitle>Mol Psychiatry</addtitle><addtitle>Mol Psychiatry</addtitle><description>Our understanding of depression and its treatment has advanced with the advent of ketamine as a rapid-acting antidepressant and the development and refinement of tools capable of selectively altering the activity of populations of neuronal subtypes. This work has resulted in a paradigm shift away from dysregulation of single neurotransmitter systems in depression towards circuit level abnormalities impacting function across multiple brain regions and neurotransmitter systems. Studies on the features of circuit level abnormalities demonstrate structural changes within the prefrontal cortex (PFC) and functional changes in its communication with distal brain structures. Treatments that impact the activity of brain regions, such as transcranial magnetic stimulation or rapid-acting antidepressants like ketamine, appear to reverse depression associated circuit abnormalities though the mechanisms underlying the reversal, as well as development of these abnormalities remains unclear. Recently developed optogenetic and chemogenetic tools that allow high-fidelity control of neuronal activity in preclinical models have begun to elucidate the contributions of the PFC and its circuitry to depression- and anxiety-like behavior. These tools offer unprecedented access to specific circuits and neuronal subpopulations that promise to offer a refined view of the circuit mechanisms surrounding depression and potential mechanistic targets for development and reversal of depression associated circuit abnormalities.</description><subject>631/378</subject><subject>692/699/476/1414</subject><subject>Antidepressants</subject><subject>Antidepressive Agents - pharmacology</subject><subject>Antidepressive Agents - therapeutic use</subject><subject>Anxiety</subject><subject>Anxiety - drug therapy</subject><subject>Anxiety - pathology</subject><subject>Behavioral Sciences</subject><subject>Biological Psychology</subject><subject>Brain</subject><subject>Depression - drug therapy</subject><subject>Depression - pathology</subject><subject>Depression, Mental</subject><subject>Ketamine</subject><subject>Ketamine - pharmacology</subject><subject>Ketamine - therapeutic use</subject><subject>Magnetic fields</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Mental depression</subject><subject>Neural Pathways - drug effects</subject><subject>Neurons</subject><subject>Neurosciences</subject><subject>Pharmacotherapy</subject><subject>Prefrontal cortex</subject><subject>Prefrontal Cortex - drug effects</subject><subject>Prefrontal Cortex - pathology</subject><subject>Psychiatry</subject><subject>Review Article</subject><subject>Transcranial magnetic stimulation</subject><issn>1359-4184</issn><issn>1476-5578</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1Ul1v1iAUJkbj5vQHeGOaeONNN6CUFi9MlkWnyRKXxXvCC6eVpS9UoMv27z313ea2aAiB8HzAOTyEvGX0kNGmP8qCNT2tKccp-7ZWz8g-E52s27brn-O-aVUtWC_2yKucLyldwfYl2Ws47aVoxD65Ok8wpBiKmSobU4HryvpkF19y5UPlYE6Qs4-hMsHhvPZQbj4iNZTkN0tZkThUzmeboEAVYEE3NJvjvExmxfMfaTFphFIlGNej1-TFYKYMb27XA3Lx5fOPk6_12ffTbyfHZ7WVtCm14YMQTjHhOsaglbzDZwMwYTjvsJRWCrMRDqwRYNig-sEpZzpQUkrbHJBPO9N52WzBWcA3m0nPyW9NutHReP0YCf6nHuOV7oTgkrZo8OHWIMVfC-Sit1gnTJMJEJeseSM5Va2iEqnvn1Av45KwEcgSHROKse4BazQTaB-GiPfa1VQfy2blKLFee_gPFg4HW4-dh8Hj-SMB2wlsijnjh97XyKhek6J3SdGYFL0mRSvUvHvYnHvFXTSQwHeEjFAYIf2t6P-uvwHIiMso</recordid><startdate>20201101</startdate><enddate>20201101</enddate><creator>Hare, Brendan D.</creator><creator>Duman, Ronald S.</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8690-8439</orcidid><orcidid>https://orcid.org/0000-0002-6502-3188</orcidid></search><sort><creationdate>20201101</creationdate><title>Prefrontal cortex circuits in depression and anxiety: contribution of discrete neuronal populations and target regions</title><author>Hare, Brendan D. ; Duman, Ronald S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c603t-a2f44d914d711e5627864ee14a227765564ab4deca4ea1f98fd9da7e9666c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>631/378</topic><topic>692/699/476/1414</topic><topic>Antidepressants</topic><topic>Antidepressive Agents - pharmacology</topic><topic>Antidepressive Agents - therapeutic use</topic><topic>Anxiety</topic><topic>Anxiety - drug therapy</topic><topic>Anxiety - pathology</topic><topic>Behavioral Sciences</topic><topic>Biological Psychology</topic><topic>Brain</topic><topic>Depression - drug therapy</topic><topic>Depression - pathology</topic><topic>Depression, Mental</topic><topic>Ketamine</topic><topic>Ketamine - pharmacology</topic><topic>Ketamine - therapeutic use</topic><topic>Magnetic fields</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Mental depression</topic><topic>Neural Pathways - drug effects</topic><topic>Neurons</topic><topic>Neurosciences</topic><topic>Pharmacotherapy</topic><topic>Prefrontal cortex</topic><topic>Prefrontal Cortex - drug effects</topic><topic>Prefrontal Cortex - pathology</topic><topic>Psychiatry</topic><topic>Review Article</topic><topic>Transcranial magnetic stimulation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hare, Brendan D.</creatorcontrib><creatorcontrib>Duman, Ronald S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Molecular psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hare, Brendan D.</au><au>Duman, Ronald S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prefrontal cortex circuits in depression and anxiety: contribution of discrete neuronal populations and target regions</atitle><jtitle>Molecular psychiatry</jtitle><stitle>Mol Psychiatry</stitle><addtitle>Mol Psychiatry</addtitle><date>2020-11-01</date><risdate>2020</risdate><volume>25</volume><issue>11</issue><spage>2742</spage><epage>2758</epage><pages>2742-2758</pages><issn>1359-4184</issn><eissn>1476-5578</eissn><abstract>Our understanding of depression and its treatment has advanced with the advent of ketamine as a rapid-acting antidepressant and the development and refinement of tools capable of selectively altering the activity of populations of neuronal subtypes. This work has resulted in a paradigm shift away from dysregulation of single neurotransmitter systems in depression towards circuit level abnormalities impacting function across multiple brain regions and neurotransmitter systems. Studies on the features of circuit level abnormalities demonstrate structural changes within the prefrontal cortex (PFC) and functional changes in its communication with distal brain structures. Treatments that impact the activity of brain regions, such as transcranial magnetic stimulation or rapid-acting antidepressants like ketamine, appear to reverse depression associated circuit abnormalities though the mechanisms underlying the reversal, as well as development of these abnormalities remains unclear. Recently developed optogenetic and chemogenetic tools that allow high-fidelity control of neuronal activity in preclinical models have begun to elucidate the contributions of the PFC and its circuitry to depression- and anxiety-like behavior. These tools offer unprecedented access to specific circuits and neuronal subpopulations that promise to offer a refined view of the circuit mechanisms surrounding depression and potential mechanistic targets for development and reversal of depression associated circuit abnormalities.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>32086434</pmid><doi>10.1038/s41380-020-0685-9</doi><tpages>17</tpages><orcidid>https://orcid.org/0000-0001-8690-8439</orcidid><orcidid>https://orcid.org/0000-0002-6502-3188</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1359-4184
ispartof Molecular psychiatry, 2020-11, Vol.25 (11), p.2742-2758
issn 1359-4184
1476-5578
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7442605
source MEDLINE; SpringerLink Journals
subjects 631/378
692/699/476/1414
Antidepressants
Antidepressive Agents - pharmacology
Antidepressive Agents - therapeutic use
Anxiety
Anxiety - drug therapy
Anxiety - pathology
Behavioral Sciences
Biological Psychology
Brain
Depression - drug therapy
Depression - pathology
Depression, Mental
Ketamine
Ketamine - pharmacology
Ketamine - therapeutic use
Magnetic fields
Medicine
Medicine & Public Health
Mental depression
Neural Pathways - drug effects
Neurons
Neurosciences
Pharmacotherapy
Prefrontal cortex
Prefrontal Cortex - drug effects
Prefrontal Cortex - pathology
Psychiatry
Review Article
Transcranial magnetic stimulation
title Prefrontal cortex circuits in depression and anxiety: contribution of discrete neuronal populations and target regions
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T14%3A11%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prefrontal%20cortex%20circuits%20in%20depression%20and%20anxiety:%20contribution%20of%20discrete%20neuronal%20populations%20and%20target%20regions&rft.jtitle=Molecular%20psychiatry&rft.au=Hare,%20Brendan%20D.&rft.date=2020-11-01&rft.volume=25&rft.issue=11&rft.spage=2742&rft.epage=2758&rft.pages=2742-2758&rft.issn=1359-4184&rft.eissn=1476-5578&rft_id=info:doi/10.1038/s41380-020-0685-9&rft_dat=%3Cgale_pubme%3EA639117945%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2471491176&rft_id=info:pmid/32086434&rft_galeid=A639117945&rfr_iscdi=true